Product combines Bacillus coagulans, prebiotic Inulin, and eight botanical compounds; enters a probiotic supplement market valued at $61.1 billion in 2023 by Grand View Research.
BOISE, Idaho, September 12, 2026 — PrimeBiome, a U.S.-based supplement brand, began U.S. distribution of a ten-ingredient probiotic gummy in September 2026. The product is positioned around the gut-skin axis — a documented area of peer-reviewed research examining the relationship between gut microbiome health and skin appearance. It is manufactured in a GMP-certified, FDA-registered U.S. facility and distributed through ClickBank authorized retail channel, an e-commerce platform operated by Click Sales, Inc., a Delaware corporation headquartered in Boise, Idaho.
The global probiotic supplement market was valued at approximately $61.1 billion in 2023, according to Grand View Research (Global Probiotic Supplements Market Report, Grand View Research, 2024; grandviewresearch.com), with projections to reach $94.5 billion by 2033 at a compound annual growth rate of 9.1 percent. These figures are sourced from a commercial market research firm and have not been independently verified.
The formula contains ten ingredients disclosed by name on the supplement facts panel: Bacillus coagulans, Inulin, Babchi, Dandelion, Fennel, Fenugreek, Lemon Balm, Organic Ceylon Ginger, Organic Lion’s Mane, and Slippery Elm Bark. Ingredients are grouped under a proprietary blend designation; individual dosages per ingredient are not separately published on the label. The product is classified by the manufacturer as non-GMO.
Scientific Background: The Gut-Skin Axis
The gut-skin axis is an active area of peer-reviewed scientific research. Published clinical literature has examined associations between gut microbiome composition and skin conditions including acne vulgaris, atopic dermatitis, and rosacea. Proposed mechanisms in the literature include systemic inflammation, altered intestinal permeability, and neuroendocrine signaling. Researchers in the field have noted that while the gut-skin relationship is supported by observational and interventional data, most published studies are limited by small sample sizes, heterogeneous methodologies, and short follow-up periods. The field is developing; no dietary supplement has received FDA approval for the treatment of dermatological or gastrointestinal disease, and supplement-format interventions are not clinically equivalent to approved pharmaceutical treatments.
The following citations reference peer-reviewed research on individual compounds present in probiotic and botanical supplement formulas. None of these studies were conducted on PrimeBiome. All were performed under conditions unaffiliated with the manufacturer. None constitute clinical evidence of this product’s efficacy. Provided for reference only.
Bacillus coagulans: Cao, J., et al. (2020). “Efficacy of Bacillus coagulans in the treatment of gastrointestinal disorders: a systematic review.” Nutrients. doi:10.3390/nu12051521. Assessed outcomes across randomized controlled trials in adult subjects measuring gastrointestinal symptoms.
Inulin (prebiotic fiber): Kolida, S., & Gibson, G.R. (2011). “Synbiotics in health and disease.” Annual Review of Food Science and Technology. doi:10.1146/annurev-food-022510-133739. Examined prebiotic fiber in adult subjects in relation to gut bacteria proliferation and microbiome balance.
Organic Lion’s Mane (Hericium erinaceus): Mori, K., et al. (2009). “Nerve growth factor-inducing activity of Hericium erinaceus.” Biological & Pharmaceutical Bulletin. doi:10.1248/bpb.32.1977. Examined Lion’s Mane extract in relation to nerve growth factor activity in adult subjects.
Organic Ceylon Ginger (Zingiber officinale): Haniadka, R., et al. (2013). “A review of the gastroprotective effects of ginger.” Food & Function. doi:10.1039/c3fo30337c. Assessed ginger in adult subjects in relation to gastrointestinal function and digestive motility.
Dandelion (Taraxacum officinale): Schütz, K., et al. (2006). “Taraxacum — a review on its phytochemical and pharmacological profile.” Journal of Ethnopharmacology. doi:10.1016/j.jep.2006.04.010. Assessed Dandelion extract in adult subjects in relation to antioxidant activity and digestive support.
Slippery Elm Bark (Ulmus rubra): Langmead, L., et al. (2002). “Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease.” Alimentary Pharmacology & Therapeutics. doi:10.1046/j.1365-2036.2002.01157.x. Assessed Slippery Elm for antioxidant activity and gastrointestinal support in adult subjects.
Lemon Balm (Melissa officinalis): Cases, J., et al. (2011). “Pilot trial of Melissa officinalis L. leaf extract.” Mediterranean Journal of Nutrition and Metabolism. doi:10.1007/s12349-010-0045-4. Examined Lemon Balm in adult subjects in relation to stress response and digestive comfort.
Fennel (Foeniculum vulgare): Badgujar, S.B., et al. (2014). “Foeniculum vulgare Mill: a review of its botany, phytochemistry, pharmacology, contemporary application, and toxicology.” BioMed Research International. doi:10.1155/2014/842674. Reviewed Fennel in relation to gastrointestinal comfort and antispasmodic activity in adult subjects.
Market Context
The global dietary supplements market was valued at approximately $177.5 billion in 2024 and is projected to reach $327.4 billion by 2033 at a compound annual growth rate of 7.0 percent, according to Precedence Research (Dietary Supplements Market Size, Share & Trends Report 2033, precedenceresearch.com, 2025). These are third-party projections and have not been independently verified.
Several supplement brands have introduced probiotic gummy products with gut-skin axis positioning in recent years. The gummy delivery format has grown within the supplement category, attributed in trade reporting to consumer preference for non-capsule formats. Probiotic formulas in this segment typically combine one or more bacterial strains with prebiotic fibers and botanical compounds, with manufacturers differentiating on the basis of strain selection, botanical composition, and delivery mechanism. A 2020 systematic review in Nutrients (Cao, J., et al., doi:10.3390/nu12051521) noted that spore-forming strains such as Bacillus coagulans exhibit greater survivability through the gastric environment compared to conventional Lactobacillus-based formats — a characteristic referenced by manufacturers in category positioning.
Product Information
The PrimeBiome gummy is taken once daily. Each production batch undergoes third-party testing for quality and purity prior to distribution. The manufacturer states the product contains no artificial stimulants, requires no refrigeration, and is classified as non-GMO and gluten-free. It is sold without a subscription or auto-ship program; all orders are processed as one-time purchases. The formula is available in single and multi-bottle supply configurations through the manufacturer’s authorized retail channel.
The manufacturer issued the following statement regarding the product’s formulation:
“The ingredients in PrimeBiome were selected based on their presence in published scientific research on gut health and the gut-skin axis. No claim is made that this formula replicates outcomes from any independently conducted study on these compounds.”
— PrimeBiome Media Relations
Manufacturing and Distribution
PrimeBiome is manufactured in a GMP-certified, FDA-registered facility in the United States under Current Good Manufacturing Practices as defined by the U.S. Food and Drug Administration. Every production batch is subject to third-party quality and purity testing prior to release for distribution. Retail transactions are processed through ClickBank (Click Sales, Inc., a Delaware corporation). ClickBank’s role as retailer does not constitute an endorsement, approval, or review of the product or any claims made in its promotion.
Regulatory Statement
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The scientific citations in this press release reference independent research on individual compounds conducted under conditions unaffiliated with the manufacturer and do not constitute clinical evidence of this product’s efficacy. Individual results may vary.
About PrimeBiome
PrimeBiome is a nutritional supplement brand founded in 2026 and headquartered in Boise, Idaho. The company produces probiotic gummy formulas for adult consumers. Its current product line consists of a ten-ingredient probiotic gummy containing Bacillus coagulans, Inulin, Babchi, Dandelion, Fennel, Fenugreek, Lemon Balm, Organic Ceylon Ginger, Organic Lion’s Mane, and Slippery Elm Bark. The brand cites published peer-reviewed research on individual ingredient compounds as the basis for its ingredient selection; no claim is made that the combined formula has been clinically tested or produces outcomes equivalent to those described in any independent study. Manufacturing takes place in a GMP-certified, FDA-registered U.S. facility with third-party quality testing applied to each batch prior to distribution.
This release does not include any third-party images. PrimeBiome and associated marks are trademarks of their respective owner; all other trademarks referenced are the property of their respective owners.
Media Contact
PrimeBiome Media Relations
support@getprimebiome.com
+1 844-236-6478
The post PrimeBiome Reviews: Ten-Ingredient Probiotic Gummy Reaches U.S. Market Targeting Gut-Skin Axis appeared first on 24 Health Times.
